| SYS | | c032870 |
|---|
| LBL | | ^^^^^nam^^22^^^^^^^^450^ |
|---|
| 005 | | 20070213111505.0 |
|---|
| 011 | | $a 0803-5326 |
|---|
| 100 | | $a 20060518d2006 m y0sloc0103 ba |
|---|
| 101 | 0- | $a eng |
|---|
| 102 | | $a SE |
|---|
| 105 | | $a a aoz 100yy |
|---|
| 200 | 1- | $a Lysosomal diseases: natural course, pathology and therapy $e understanding the biology of X-linked diseases. Reversibility of cellular/organ pathology in LSDs. CNS pathology in Fabry disease. 5th international symposium, Valencia, April 2005. Proceedings $f guest eds. Michael Beck, Timothy M. Cox, Atul B. Mehta, Urs Widmer |
|---|
| 210 | | $a Stockholm $c Taylor & Francis $d 2006 |
|---|
| 215 | | $a 144 s. $c il., obr., grafy, tab. |
|---|
| 225 | 2- | $a Acta Paediatrica $e international journal of paediatrics $v suppl. 451 |
|---|
| 320 | | $a Obsahuje bibliogr. odkazy |
|---|
| 541 | 1- | $a Lyzozómové choroby: priebeh, patológia a terapia $e pochopenie biológie chorôb viazaných na chromozóm X. Reverzibilita bunkovej/orgánovej patológie pri lyzozómových chorobách (LDSs). Patológia CNS pri Fabryho chorobe |
|---|
| 606 | 1- | $a choroby genetické, viazané na chromozóm X $x genetika $2 mesh $3 sllk_un_auth*d040181 $9 . |
|---|
| 606 | 1- | $a choroby lyzozómové $x patológia $x terapia $x genetika $2 mesh $3 sllk_un_auth*d016464 $9 . |
|---|
| 606 | 2- | $a inaktivácia chromozómu X $2 mesh $3 sllk_un_auth*d049951 $9 . |
|---|
| 606 | 2- | $3 sllk_un_auth*d012720 $a stupeň závažnosti ochorenia $9 . $2 mesh |
|---|
| 606 | 2- | $a Fabryho choroba $x patológia $x diagnostika $x genetika $2 mesh $3 sllk_un_auth*d000795 $9 . |
|---|
| 606 | 2- | $a glykogenóza, typ II $x patológia $2 mesh $3 sllk_un_auth*d006009 $9 . |
|---|
| 606 | 2- | $a nefropatie diabetické $2 mesh $3 sllk_un_auth*d003928 $9 . |
|---|
| 606 | 2- | $a enzýmy $x použitie terapeutické $2 mesh $3 sllk_un_auth*d004798 $9 . |
|---|
| 606 | 2- | $a Gaucherova choroba $x patofyziológia $x genetika $x diagnostika $2 mesh $3 sllk_un_auth*d005776 $9 . |
|---|
| 606 | 2- | $3 sllk_un_auth*d018832 $a chaperóny molekulárne $x použitie terapeutické $9 . $2 mesh |
|---|
| 606 | 2- | $a mukopolysacharidózy $2 mesh $3 sllk_un_auth*d009083 $9 . |
|---|
| 608 | | $3 sllk_un_auth*d016423 $a kongres $2 mesh |
|---|
| 675 | | $a 616-008-053.2(063) $v 2. $z slo |
|---|
| 702 | -1 | $a Beck $b Michael $3 sllk_un_auth*p0055763 $4 340 $p Div. of Cardiology and Div. of Lysosomal Storage Diseases, Univ. of Mainz, Mainz, Germany |
|---|
| 702 | -1 | $a Cox $b Timothy M. $3 sllk_un_auth*p0028690 $4 340 $p Dept. of Medicine, Univ. of Cambridge, Addenbrooke's Hospital, Cambridge, U.K. |
|---|
| 702 | -1 | $a Mehta $b Atul B. $3 sllk_un_auth*p0044745 $4 340 |
|---|
| 702 | -1 | $a Widmer $b Urs $3 sllk_un_auth*p0044746 $4 340 $p Dept. of Medicine, University Hospital, Zurich, Switzerland |
|---|
| 712 | 12 | $a International symposium on Lysosomal Storage Diseases $d 5. $e Valencia, Španielsko $f 2005 $3 sllk_un_auth*k0003689 $4 070 |
|---|
| 801 | -0 | $a SK $b BA006 $c 20060518 $g AACR2 |
|---|
